NO325828B1 - Anvendelse av et antistoff dannet mot et antigen. - Google Patents

Anvendelse av et antistoff dannet mot et antigen. Download PDF

Info

Publication number
NO325828B1
NO325828B1 NO19964650A NO964650A NO325828B1 NO 325828 B1 NO325828 B1 NO 325828B1 NO 19964650 A NO19964650 A NO 19964650A NO 964650 A NO964650 A NO 964650A NO 325828 B1 NO325828 B1 NO 325828B1
Authority
NO
Norway
Prior art keywords
lag
cells
antigen
mhc class
antibody
Prior art date
Application number
NO19964650A
Other languages
English (en)
Norwegian (no)
Other versions
NO964650D0 (no
NO964650L (no
Inventor
Florence Faure
Thierry Hercend
Bertrand Huard
Frederic Triebel
Original Assignee
Roussy Inst Gustave
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave filed Critical Roussy Inst Gustave
Publication of NO964650D0 publication Critical patent/NO964650D0/no
Publication of NO964650L publication Critical patent/NO964650L/no
Publication of NO325828B1 publication Critical patent/NO325828B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19964650A 1994-05-06 1996-11-04 Anvendelse av et antistoff dannet mot et antigen. NO325828B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9405643 1994-05-06
PCT/FR1995/000593 WO1995030750A2 (fr) 1994-05-06 1995-05-05 Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype

Publications (3)

Publication Number Publication Date
NO964650D0 NO964650D0 (no) 1996-11-04
NO964650L NO964650L (no) 1997-01-06
NO325828B1 true NO325828B1 (no) 2008-07-28

Family

ID=9463004

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19964650A NO325828B1 (no) 1994-05-06 1996-11-04 Anvendelse av et antistoff dannet mot et antigen.

Country Status (18)

Country Link
US (3) US5955300A (pt)
EP (1) EP0758383B1 (pt)
JP (1) JP3700859B2 (pt)
KR (1) KR100257466B1 (pt)
CN (1) CN1110557C (pt)
AT (1) ATE352617T1 (pt)
BR (1) BR9507618A (pt)
CA (1) CA2189657C (pt)
DE (1) DE69535375T2 (pt)
DK (1) DK0758383T3 (pt)
ES (1) ES2281899T3 (pt)
IL (1) IL113617A (pt)
MX (1) MX9605365A (pt)
NO (1) NO325828B1 (pt)
PT (1) PT758383E (pt)
RU (1) RU2178306C2 (pt)
WO (1) WO1995030750A2 (pt)
ZA (1) ZA953629B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197524B1 (en) * 1995-07-21 2001-03-06 Institute National De La Sante Et De La Recherche Medicale Methods for detecting, identifying, isolating, and selectively labelling and targeting TH1 lymphocyte by means of the LAG-3 protein
IL130123A (en) * 1996-11-28 2007-07-24 Roussy Inst Gustave LAG-3 protein mutants, their expression, use and method of production
PT941329E (pt) * 1996-11-29 2004-11-30 Applied Research Systems Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)
EP0900841A1 (en) * 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6434012B2 (en) * 2000-02-11 2002-08-13 Tyco Electronics Logistics Ag Circuit board interconnect
AU5943201A (en) * 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
EP1575480A4 (en) * 2002-02-22 2008-08-06 Genentech Inc COMPOSITIONS AND METHODS OF TREATING IMMUNE-INFLAMMATORY DISEASES
PL1897548T5 (pl) 2003-02-28 2025-03-17 The Johns Hopkins University Regulacja komórek T
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
FR2868781B1 (fr) * 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP2044949A1 (en) * 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
JP6595458B2 (ja) 2013-09-20 2019-10-23 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
SI3148579T1 (sl) 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
US11786457B2 (en) 2015-01-30 2023-10-17 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
HUE068868T2 (hu) 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
WO2017087780A1 (en) 2015-11-20 2017-05-26 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
IL260021B (en) 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
US11045547B2 (en) 2015-12-16 2021-06-29 Merck Sharp & Dohme Corp. Anti-LAG3 antibodies and antigen-binding fragments
EP4414484A3 (en) * 2016-02-04 2025-01-15 Trianni, Inc. Enhanced production of immunoglobulins
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US11155617B2 (en) 2016-06-23 2021-10-26 Jiangsu Hengrui Medicine Co., Ltd. LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
JP7066696B2 (ja) 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗ｌａｇ－３抗体及びその使用方法
PH12019500668B1 (en) * 2016-10-13 2023-12-06 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anti-lag-3 antibodies and compositions
US12162938B2 (en) 2016-10-28 2024-12-10 Merck Sharp & Dohme Llc Purification process for removal of tyrosine sulfation antibody variants; purified compositions
WO2018083087A2 (en) 2016-11-02 2018-05-11 Glaxosmithkline Intellectual Property (No.2) Limited Binding proteins
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
UA129904C2 (uk) 2017-04-05 2025-09-10 Ле Лаборатуар Сервьє Комбінація антитіла до tim-3 й антитіла до pd-1 для лікування раку
US11339218B2 (en) * 2017-05-10 2022-05-24 Zhejiang Shimai Pharmaceutical Co., Ltd. Human monoclonal antibodies against LAG3 and uses thereof
ES2965352T3 (es) 2017-05-30 2024-04-12 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
CN110678200B (zh) 2017-05-30 2024-05-17 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
WO2019046225A1 (en) 2017-08-30 2019-03-07 Phanes Therapeutics, Inc. ANTI-LAG-3 ANTIBODIES AND USES THEREOF
CA3085656A1 (en) * 2017-12-22 2019-06-27 Jiangsu Hengrui Medicine Co., Ltd. Lag-3 antibody pharmaceutical composition and use thereof
EP3969040A1 (en) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
CN115340606B (zh) * 2019-05-31 2023-12-19 瑞阳(苏州)生物科技有限公司 与人lag-3蛋白结合的抗体及其编码基因和应用
CN110950966B (zh) * 2019-12-13 2020-12-11 启辰生生物科技(珠海)有限公司 融合蛋白、编码核酸和细胞及用途
KR20230093282A (ko) 2020-10-23 2023-06-27 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 lag-3 길항제 요법
EP4680342A1 (en) 2023-03-13 2026-01-21 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
AU2024379466A1 (en) 2023-11-15 2026-04-23 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
WO2026035866A1 (en) 2024-08-07 2026-02-12 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
EP0537293A4 (en) * 1990-07-02 1993-09-08 Bristol-Myers Company Ligand for cd28 receptor on b cells and methods

Also Published As

Publication number Publication date
JP3700859B2 (ja) 2005-09-28
DE69535375D1 (de) 2007-03-15
RU2178306C2 (ru) 2002-01-20
IL113617A (en) 2007-09-20
EP0758383B1 (fr) 2007-01-24
CN1155904A (zh) 1997-07-30
AU708825B2 (en) 1999-08-12
DK0758383T3 (da) 2007-05-29
EP0758383A1 (fr) 1997-02-19
ATE352617T1 (de) 2007-02-15
NO964650D0 (no) 1996-11-04
MX9605365A (es) 1997-12-31
WO1995030750A3 (fr) 1995-12-21
ES2281899T3 (es) 2007-10-01
ZA953629B (en) 1996-11-05
CA2189657A1 (fr) 1995-11-16
DE69535375T2 (de) 2007-11-08
JPH09508023A (ja) 1997-08-19
WO1995030750A8 (fr) 1999-07-29
IL113617A0 (en) 1995-08-31
WO1995030750A2 (fr) 1995-11-16
PT758383E (pt) 2007-05-31
BR9507618A (pt) 1997-08-19
CN1110557C (zh) 2003-06-04
US5955300A (en) 1999-09-21
AU2570195A (en) 1995-11-29
CA2189657C (fr) 2002-03-12
USRE38313E1 (en) 2003-11-11
KR100257466B1 (ko) 2000-07-01
KR970702917A (ko) 1997-06-10
NO964650L (no) 1997-01-06
US6143273A (en) 2000-11-07

Similar Documents

Publication Publication Date Title
NO325828B1 (no) Anvendelse av et antistoff dannet mot et antigen.
US11414490B2 (en) Regulatory T cell mediator proteins and uses thereof
AU2019203823B2 (en) CS1-specific chimeric antigen receptor engineered immune effector cells
Azuma et al. Requirements for CD28-dependent T cell-mediated cytotoxicity
US7034121B2 (en) Antibodies against CTLA4
Hewitt et al. Major histocompatibility complex independent clonal T cell anergy by direct interaction of Staphylococcus aureus enterotoxin B with the T cell antigen receptor.
US7745215B2 (en) Methods and compositions for expanding T regulatory cells
US20020127231A1 (en) Soluble divalent and multivalent heterodimeric analogs of proteins
KR20010031205A (ko) 가용성 주요 조직적합 복합체 및 그의 사용 방법
US20230015969A1 (en) Regulatory t cell mediator proteins and uses thereof
Subramanyam et al. Soluble human lymphocyte activation gene-3 modulates allospecific T cell responses.
US20030086932A1 (en) Surface-bound antigen binding portions of antibodies that bind to CTLA-4 and CD28 and uses therefor
WO1996017939A1 (en) Isolated herpesvirus saimiri proteins that bind mhc class ii molecules
Foreman et al. Expression of costimulatory molecules CD80 and/or CD86 by a Kaposi's sarcoma tumor cell line induces differential T-cell activation and proliferation
Zuckerman et al. Identification of a unique costimulatory activity for murine T helper 1 T cell clones.
US20020182727A1 (en) Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells
WO1997035004A1 (en) Cell stimulation
KR100544449B1 (ko) 단백질의 가용성2가 및 다가 헤테로 이량체 유사체
Chiampanichayakul1ą et al. Engagement of Na, K-ATPase b3 subunit by a specific mAb suppresses T and B lymphocyte activation

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

MK1K Patent expired